



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Parkinson's study patients reach 42 weeks post NTCELL[®] implant

Data shows treatment has stopped the progression of Parkinson's

27 October 2015 – Sydney, Australia & Auckland, New Zealand – The four patients who took part in Living Cell Technologies Limited's Phase I/IIa clinical study of NTCELL for Parkinson's disease have all reached the milestone of 42 weeks post-implant. All four patients remain well, and there are no safety concerns.

In all four patients NTCELL treatment has stopped the progression of Parkinson's disease as measured by globally accepted and validated neurological rating scales.

In all four patients the 42 week post-implant data show there is a clinically and statistically significant improvement in the patients' neurological score from their pre-implant baseline. That improvement is equivalent to approximately 5 years of Parkinson's disease remission and is maintained 74 weeks after NTCELL transplant in the first patient.

Data from the ongoing monitoring of the four patients was measured by validated neurological rating scales and questionnaires, including the Unified Parkinson's Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale (UDysRS) and the Parkinson's Disease Quality of Life Questionnaire (PDQ-39). These scales and questionnaires are used to assess improvements in patients' movement abnormalities, other physical symptoms, well-being and ability to perform everyday tasks.

Dr Ken Taylor, Chief Executive, says the continued improvement of the patients is pleasing.

"We are delighted with the continued positive outcome of the study to date. It certainly adds anticipation and motivation to the planned Phase IIb study. The Phase IIb study will confirm the effective dose of NTCELL, define any placebo component of the response and further identify the Parkinson's disease patient sub group we would initially target."

For further information: www.lctglobal.com

At the company:	Media enquires:
Ken Taylor	Rachael Joel
Chief Executive	Botica Butler Raudon Partners
Tel: +64 9 276 2690	Tel: +64 9 303 3862
Mobile: +64 21 796000	Mobile: +64 21 403 504
ktaylor@lctglobal.com	rachaelj@botica.co.nz

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is a New Zealand biotechnology company focused on discovering, developing and commercialising regenerative cell treatments which restore function using naturally occurring cells.

LCT's lead product NTCELL[®] is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing neurotrophic factors to prevent and repair disease induced nerve degeneration.

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy. A Phase IIb trial has been designed to further evaluate NTCELLs potential as a disease-modifying treatment for patients with Parkinson's disease.

NTCELL has the potential to be used in a number of other central nervous system degenerative diseases such as Huntington's, Alzheimer's and motor neurone diseases.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.